- Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
-
Jeong S, Park SH
- KMID: 2471043
- Immune Netw.
- 2020 Feb;20(1):e3.
- doi: 10.4110/in.2020.20.e3
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
